PTC Therapeutics Inc
PTCT51.660USD
-0.470-0.90%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
4.09BMarktkapitalisierung
6.88KGV TTM
mehr Informationen über PTC Therapeutics Inc Unternehmen
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Unternehmensinformationen
BörsenkürzelPTCT
Name des UnternehmensPTC Therapeutics Inc
IPO-datumJun 20, 2013
CEODr. Matthew B. Klein, M.D.
Anzahl der mitarbeiter939
WertpapierartOrdinary Share
GeschäftsjahresendeJun 20
Addresse500 Warren Corporate Center Drive
StadtWARREN
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl07059
Telefon19082227000
Websitehttps://www.ptcbio.com/
BörsenkürzelPTCT
IPO-datumJun 20, 2013
CEODr. Matthew B. Klein, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
126.60K
+0.53%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
87.68K
-13.92%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
60.20K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
54.45K
-3.13%
Mr. Eric Pauwels
Mr. Eric Pauwels
Chief Business Officer
Chief Business Officer
19.79K
-16.96%
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
18.36K
-12.05%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
16.17K
+13.98%
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
16.17K
+2.10%
Ms. Emma Reeve
Ms. Emma Reeve
Independent Director
Independent Director
12.87K
+2.66%
Ms. Stephanie S. Okey
Ms. Stephanie S. Okey
Independent Director
Independent Director
6.53K
+5.37%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
126.60K
+0.53%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
87.68K
-13.92%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
60.20K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
54.45K
-3.13%
Mr. Eric Pauwels
Mr. Eric Pauwels
Chief Business Officer
Chief Business Officer
19.79K
-16.96%
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
18.36K
-12.05%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
413.04M
51.20%
Non-US
393.74M
48.80%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.84%
RTW Investments L.P.
9.44%
BlackRock Institutional Trust Company, N.A.
7.50%
Armistice Capital LLC
6.86%
Wellington Management Company, LLP
6.84%
Other
58.52%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.84%
RTW Investments L.P.
9.44%
BlackRock Institutional Trust Company, N.A.
7.50%
Armistice Capital LLC
6.86%
Wellington Management Company, LLP
6.84%
Other
58.52%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
40.10%
Investment Advisor
34.56%
Hedge Fund
20.09%
Research Firm
5.93%
Corporation
1.75%
Venture Capital
0.78%
Pension Fund
0.74%
Individual Investor
0.71%
Bank and Trust
0.31%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
542
83.25M
105.04%
-7.03M
2025Q1
551
82.28M
103.88%
-8.58M
2024Q4
513
80.63M
102.26%
-7.88M
2024Q3
503
82.04M
106.59%
-9.34M
2024Q2
498
82.97M
107.86%
-13.36M
2024Q1
493
89.17M
116.42%
-6.48M
2023Q4
485
88.17M
116.52%
-2.91M
2023Q3
477
85.04M
112.75%
-2.96M
2023Q2
478
84.63M
112.42%
-161.84K
2023Q1
486
82.00M
110.89%
-2.44M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
8.59M
10.84%
-571.45K
-6.24%
Mar 31, 2025
RTW Investments L.P.
7.48M
9.44%
+90.00K
+1.22%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.95M
7.5%
-111.10K
-1.83%
Mar 31, 2025
Armistice Capital LLC
5.43M
6.86%
-943.16K
-14.79%
Mar 31, 2025
Wellington Management Company, LLP
5.42M
6.84%
+632.05K
+13.20%
Mar 31, 2025
Janus Henderson Investors
2.92M
3.68%
+590.81K
+25.40%
Mar 31, 2025
TD Securities, Inc.
2.61M
3.3%
-673.53K
-20.49%
Mar 31, 2025
State Street Global Advisors (US)
2.45M
3.1%
-253.10K
-9.35%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.87M
2.36%
+76.87K
+4.28%
Mar 31, 2025
Driehaus Capital Management, LLC
1.51M
1.91%
+471.59K
+45.30%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Neuroscience and Healthcare ETF
4.12%
Invesco Biotechnology & Genome ETF
2.71%
ALPS Medical Breakthroughs ETF
2.62%
Virtus LifeSci Biotech Products ETF
1.85%
Harbor Human Capital Factor US Small Cap ETF
1.71%
Tema Neuroscience and Mental Health ETF
1.56%
Invesco Dorsey Wright Healthcare Momentum ETF
1.38%
Global X Guru Index ETF
1.29%
SPDR S&P Biotech ETF
1.21%
VictoryShares Small Cap Free Cash Flow ETF
0.88%
Mehr Anzeigen
iShares Neuroscience and Healthcare ETF
Anteil4.12%
Invesco Biotechnology & Genome ETF
Anteil2.71%
ALPS Medical Breakthroughs ETF
Anteil2.62%
Virtus LifeSci Biotech Products ETF
Anteil1.85%
Harbor Human Capital Factor US Small Cap ETF
Anteil1.71%
Tema Neuroscience and Mental Health ETF
Anteil1.56%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil1.38%
Global X Guru Index ETF
Anteil1.29%
SPDR S&P Biotech ETF
Anteil1.21%
VictoryShares Small Cap Free Cash Flow ETF
Anteil0.88%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
